A Study of PLX51107 in Advanced Malignancies

Inclusion Criteria:

1. Confirmed diagnosis of a relapsed or refractory malignancy in 1 of 2 treatment groups:

1. Group A: Subjects with any solid tumor (including lymphomas).

2. Group B: Subjects with relapsed or refractory AML, Subjects with relapsed or
refractory high-risk MDS, defined as revised International Prognostic Scoring
System (IPSS-R) intermediate or greater disease.

2. Age ≥18 years.

3. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.

4. Life expectancy ≥3 months in the judgment of the investigator.

5. Adequate organ function.

6. Group A subjects must have measurable or evaluable disease per the appropriate disease
criteria.

7. Women of child-bearing potential must have a negative serum pregnancy test at
Screening and must agree to use an effective form of contraception from the time of
the negative pregnancy test up to 6 months after the last dose of study drug.
Effective forms of contraception include abstinence, hormonal contraceptive in
conjunction with a barrier method, or a double barrier method. Women of
non-child-bearing potential may be included if they are either surgically sterile or
have been postmenopausal for ≥1 year.

8. Fertile men must agree to use an effective method of birth control during the study
and for up to 6 months after the last dose of study drug.

9. All associated clinically significant toxicity from previous cancer therapy must be
resolved (to ≤Grade 1 or baseline) prior to study treatment administration (Grade 2
alopecia is allowed).

10. Willingness and ability to provide written informed consent prior to any study‑related
procedures and to comply with all study requirements.

Exclusion Criteria:

1. Prior exposure to a bromodomain inhibitor, such as OTX-015 or CPI-0610.

2. Allogenic or autologous transplant for hematological malignancy with infusion of stem
cells within 90 days before Cycle 1 Day 1, or on active immunosuppressive therapy for
graft-versus-host disease (GVHD) or GVHD prophylaxis within 2 weeks of Cycle 1 Day 1.

3. Known uncontrolled fungal, bacterial, and/or viral infection ≥Grade 2.

4. Uncontrolled autoimmune hemolytic anemia or thrombocytopenia.

5. For Group A: Subjects with a history of brain metastases are ineligible. This includes
previously treated brain metastases. For Group B (subjects with AML): Active
symptomatic CNS involvement of AML. Subjects with previously treated leptomeningeal
disease that has been effectively treated are eligible.

6. A diagnosis of acute promyelocytic leukemia (APL) or chronic myeloid leukemia (CML) in
blast crisis.

7. Known or suspected allergy to the investigational agent or any agent given in
association with this trial.

8. Women who are pregnant or are breast feeding.

9. Clinically significant cardiac disease

10. Inability to take oral medication or significant nausea and vomiting, malabsorption,
or significant small bowel resection that, in the opinion of the Investigator, would
preclude adequate absorption.

11. Subject with known human immunodeficiency virus (HIV), hepatitis B virus (HBV), or
hepatitis C virus (HCV) infection or is known to be a carrier of hepatitis B or C.

12. Strong CYP3A4 and CYP2C8 inhibitors or inducers or CYP3A4 substrate drugs with a
narrow therapeutic range taken within 14 days or 5 drug half-lives before start of
study drug.

13. Active secondary malignancy

14. Major surgery or significant traumatic injury within 14 days prior to therapy

15. Receipt of anti-cancer therapy 14 days prior to Cycle 1 Day 1

16. Presence of any other medical, psychological, familial, sociological, or geographic
condition potentially hampering compliance with the study protocol Subjects who are
participating in any other therapeutic clinical study (observational or registry
trials are allowed).

17. Subjects who have Burkitt's lymphoma or Burkitt-like lymphoma.

18. Subjects on active anticoagulation therapy including warfarin, factor Xa inhibitors,
thrombin inhibitors, or heparin.

19. Subjects with documented hepatic metastases involving >50% of the hepatic parenchyma.